Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157.
Dobric. Ivan I; Drvis. Petar P; Petrovic. Igor I; Shejbal. Drazen D; Brcic. Luka L; Blagaic. Alenka Boban AB; Batelja. Lovorka L; Sever. Marko M; Kokic. Neven N; Tonkic. Ante A; Zoricic. Ivan I; Mise. Sandro S; Staresinic. Mario M; Radic. Bozo B; Jakir. Ana A; Babel. Jaksa J; Ilic. Spomenko S; Vuksic. Tihomir T; Jelic. Ivan I; Anic. Tomislav T; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 administered daily (10 µg/kg IP or ~0.16 µg/ml in drinking water) eliminated macroscopic and microscopic signs of esophagitis in rats.
- The peptide restored normal pressure in both the pyloric sphincter and the lower esophageal sphincter, even when given orally via drinking water.
- In healthy rats, BPC‑157 increased lower esophageal sphincter pressure and decreased pyloric sphincter pressure, whereas ranitidine showed no effect.
Practical Outcomes
- For biohackers interested in gut and esophageal health, this study suggests that low‑dose BPC‑157 taken orally could help heal esophagitis and balance sphincter pressures, at least in animal models. The oral route (adding the peptide to water) was effective, which aligns with how many enthusiasts administer BPC‑157. However, human data are lacking, so any protocol should start with conservative dosing (e.g., 200‑500 µg per day) and monitor effects closely.
Summary
In rats that develop long‑lasting throat inflammation because their stomach valve (pyloric sphincter) stops working, giving the peptide BPC‑157 (either by injection, in drinking water, or directly into the stomach) healed the inflammation and restored normal pressure in both the stomach valve and the lower esophageal valve. The same peptide also raised the pressure of the lower esophageal valve in healthy rats while lowering stomach‑valve pressure. A common acid‑blocking drug, ranitidine, did not help.
Abstract
Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters. Throughout the esophagitis experiment, gastric pentadecapeptide BPC 157 (PL 14736) is given intraperitoneally once a day (10 microg/kg, 10 ng/kg, last application 24 h before assessment), or continuously in drinking water at 0.16 microg/ml, 0.16 ng/ml (12 ml/rat per day), or directly into the stomach 5 min before pressure assessment (a water manometer connected to the drainage port of a Foley catheter implanted into the stomach either through an esophageal or duodenal incision). This treatment alleviates i) the esophagitis (macroscopically and microscopically, at either region or interval), ii) the pressure in the pyloric sphincter, and iii) the pressure in the lower esophageal sphincter (cmH2O). In the normal rats it increases lower esophageal sphincter pressure, but decreases the pyloric sphincter pressure. Ranitidine, given using the same protocol (50 mg/kg, intraperitoneally, once daily; 0.83 mg/ml in drinking water; 50 mg/kg directly into the stomach) does not have an effect in either rats with esophagitis or in normal rats.
Study Information
pubmed
2007
2007-04-24T00:00:00.000Z
10.1254/jphs.fp0061322